^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Ogivri (trastuzumab-dkst) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/12/2018
Excerpt:
Ogivri in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
Secondary therapy:
capecitabine; cisplatin + 5-fluorouracil
